Why Many Interventions Improve a Biomarker Without Altering the Underlying Condition Surrogate Markers vs True Outcomes Clinical research often relies

The modern pharmaceutical and scientific job market, dear reader, has developed a peculiar affliction—no, not another variant, but something

It is not often that the bounds of acceptable discourse are described in terms of architecture. Yet the Overton Window—

10 Slides You'll Always See If you've been pitched by more than three biotech startups in

Why constant reinvention is both vital—and a sign you may have no idea what you're doing Once

The second quarter of 2025 saw a surge in mergers and acquisitions (M&A) within the pharmaceutical and biotechnology

It is a truth almost universally acknowledged—except, perhaps, in FDA review meetings—that no credible scientist gets funded anymore

The decades-long puzzle of protein folding In the pantheon of scientific challenges, few have loomed as large or as stubborn

When a small Berlin startup launched an obesity therapy app a few years ago, investors hailed it as a potential

Real-World Data (RWD) is the equivalent of field notes in anthropology: messy, unstructured, but full of valuable insights about how